Brokerages forecast that Kindred Biosciences Inc (NASDAQ:KIN) will announce ($0.42) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Kindred Biosciences’ earnings, with estimates ranging from ($0.43) to ($0.40). Kindred Biosciences reported earnings of ($0.35) per share in the same quarter last year, which suggests a negative year over year growth rate of 20%. The firm is scheduled to announce its next earnings report on Thursday, March 7th.

On average, analysts expect that Kindred Biosciences will report full year earnings of ($1.59) per share for the current financial year, with EPS estimates ranging from ($1.65) to ($1.54). For the next year, analysts expect that the business will report earnings of ($1.44) per share, with EPS estimates ranging from ($1.46) to ($1.42). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that that provide coverage for Kindred Biosciences.

Kindred Biosciences (NASDAQ:KIN) last announced its earnings results on Wednesday, November 7th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. The business had revenue of $0.64 million during the quarter.

Several research firms recently commented on KIN. Cantor Fitzgerald reiterated a “buy” rating and issued a $20.00 price objective on shares of Kindred Biosciences in a research note on Thursday, August 9th. BidaskClub upgraded Kindred Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, October 18th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Kindred Biosciences in a research note on Monday, August 13th. Finally, Zacks Investment Research downgraded Kindred Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, August 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Kindred Biosciences presently has a consensus rating of “Buy” and a consensus target price of $19.35.

Kindred Biosciences stock traded down $0.42 during trading on Friday, hitting $12.13. The stock had a trading volume of 1,169 shares, compared to its average volume of 122,367. Kindred Biosciences has a 1 year low of $7.45 and a 1 year high of $15.75. The company has a market cap of $425.61 million, a price-to-earnings ratio of -10.02 and a beta of 0.23.

In other Kindred Biosciences news, insider Richard Chin sold 40,000 shares of the stock in a transaction on Monday, October 1st. The stock was sold at an average price of $13.28, for a total transaction of $531,200.00. Following the sale, the insider now owns 2,026,071 shares in the company, valued at $26,906,222.88. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Raymond Townsend sold 3,000 shares of the stock in a transaction on Wednesday, September 26th. The stock was sold at an average price of $13.32, for a total value of $39,960.00. Following the sale, the director now owns 27,813 shares in the company, valued at approximately $370,469.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 123,000 shares of company stock worth $1,689,560. 15.96% of the stock is owned by company insiders.

Large investors have recently bought and sold shares of the business. Metropolitan Life Insurance Co. NY bought a new position in shares of Kindred Biosciences in the second quarter worth $103,000. Tower Research Capital LLC TRC increased its holdings in shares of Kindred Biosciences by 764.3% in the second quarter. Tower Research Capital LLC TRC now owns 9,671 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 8,552 shares during the period. Paloma Partners Management Co bought a new position in shares of Kindred Biosciences in the second quarter worth $119,000. Meeder Asset Management Inc. increased its holdings in shares of Kindred Biosciences by 90.1% in the third quarter. Meeder Asset Management Inc. now owns 8,698 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 4,122 shares during the period. Finally, MetLife Investment Advisors LLC bought a new position in shares of Kindred Biosciences in the second quarter worth $146,000. Hedge funds and other institutional investors own 66.43% of the company’s stock.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc, a biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline includes small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates comprise Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Featured Story: How Important is Technical Analysis of Stocks

Get a free copy of the Zacks research report on Kindred Biosciences (KIN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.